Aspirin controlled release - New Haven Pharmaceuticals

Drug Profile

Aspirin controlled release - New Haven Pharmaceuticals

Alternative Names: Aspirin slow-release - New Haven Pharmaceuticals; Durlaza; NHP-554C

Latest Information Update: 10 Feb 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator New Haven Pharmaceuticals
  • Class Antiplatelets; Antipyretics; Antirheumatics; Nonsteroidal anti-inflammatories; Salicylic acids; Small molecules
  • Mechanism of Action Cyclooxygenase inhibitors; Nitric oxide stimulants; Platelet aggregation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Cardiovascular disorders; Stroke

Most Recent Events

  • 07 Feb 2017 Aspirin controlled release licensed to Espero Pharmaceuticals worldwide
  • 15 Dec 2015 Launched for Cardiovascular disorders (Prevention) in USA (PO)
  • 15 Dec 2015 Launched for Stroke (Prevention) in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top